Inflammide

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inflammide

Property Description
Active ingredient Budesonide
Pharmacological class Synthetic Glucocorticoid (Corticosteroid)
Form Inhalation suspension, Nasal spray, Oral capsules, Rectal foam
General Purpose Local Anti-Inflammatory Action
Origin Synthetic

What Type of Medicine is Inflammide (Budesonide)?

Inflammide is a prescription-only medication whose active ingredient is Budesonide, a substance classified as a synthetic glucocorticoid. This compound belongs to the broader class of corticosteroids and is engineered for highly localized anti-inflammatory action. The substance is a synthetic derivative, clinically recognized for its high affinity to glucocorticoid receptors, which supports its local effect in various body tissues.

Composition and Available Dosage Forms

Inflammide is a single-ingredient product available in multiple specialized dosage forms for targeted delivery of Budesonide. The available preparations include a pressurized inhalation suspension or dry powder (for the pulmonary route), a nasal spray (intranasal), and specialized forms like extended-release oral capsules or rectal foam/suppositories. This range of delivery methods underscores Budesonide's primary differentiation as an agent whose therapeutic application relies on direct, topical delivery to the inflamed tissue.


General Purpose: Anti-Inflammatory Action

The fundamental purpose of Inflammide is to serve as a local anti-inflammatory agent by modulating the immune response in affected tissues. Glucocorticoids, as a class, possess a high local anti-inflammatory action. Budesonide is specifically known for its rapid systemic clearance via high first-pass metabolism, a factor that helps minimize the systemic exposure commonly associated with older steroids. This action translates into the general benefit of relieving associated symptoms such as tissue swelling, irritation, and reactivity, thereby stabilizing the function of the inflamed area without the generalized effects of systemic treatments.

Regulatory References

  1. Budesonide - eEML
  2. Kinpeygo EPAR (Budesonide)

What side effects are possible with Inflammide?

Possible Side Effects and Safety Information

The safety profile for Inflammide (Budesonide) is structured according to formal regulatory classifications, detailing known adverse reactions by frequency and organ system as documented by authorities like the EMA and FDA. As a local anti-inflammatory, its profile lists reactions commonly observed at the site of application.


Adverse Reactions by Frequency

Classification Examples of Documented Adverse Reactions
Common Oral/pharyngeal candidiasis, headache, nausea, throat irritation, cough, dyspepsia, skin reactions.
Uncommon Anxiety, depression, restlessness, insomnia, cataract, glaucoma, muscle cramps.
Rare Systemic glucocorticoid effects (including HPA axis suppression), Cushingoid features, growth retardation in children.

Serious Safety Considerations

The most clinically significant adverse reactions, though rare with localized formulations, involve the potential for systemic glucocorticoid effects. These include adrenal suppression and the development of Cataracts or Glaucoma. Such risks are primarily associated with prolonged exposure or high doses.

Population and Contextual Safety Notes

Official labeling addresses specific populations and usage contexts. Patients with severe hepatic impairment may face an increased risk of systemic effects due to impaired metabolism, which can elevate circulating levels of the drug. In the pediatric population, the potential for growth retardation is a documented risk requiring specific monitoring. Caution is also advised regarding co-administration with strong CYP3A4 inhibitors, as this interaction significantly increases the exposure to Budesonide and elevates the risk of systemic adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose with Inflammide as a serious medical emergency, primarily due to the risk of life-threatening or fatal respiratory depression. This is characterized by shallow, slowed, or difficult breathing. The severity of overdose is compounded by the fact that even accidental ingestion of a single dose, particularly by children, may result in a fatal outcome.

Immediate medical help is required in all suspected overdose scenarios. If you suspect an overdose has occurred—whether from a single large amount or from accidental ingestion—call local emergency services (e.g., 911) immediately.

Overdose Manifestations
Life-threatening respiratory depression
Other CNS depressant effects

In the event of an overdose, management typically involves immediate supportive care for the respiratory system. Patients must be carefully monitored for signs of respiratory depression, especially following any recent change in medication or dosage. The high-risk nature, including the possibility of death from accidental exposure, underscores the necessity of urgent professional medical intervention.

Therapeutic Uses of Inflammide

What Inflammide Treats — Main Uses and Benefits

Inflammide is commonly used in areas where short-term symptom management is appropriate for symptoms related to inflammatory or irritative states. This class of medication is relevant for easing symptoms like pain, tenderness, swelling, and stiffness. It is relevant for managing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and inflammatory states in conditions like osteoarthritis, rheumatoid arthritis, gout attacks, and post-procedural inflammation.

“Inflammide is applied in scenarios where additional management of discomfort is required, helping to improve day-to-day comfort during symptomatic periods.”

The medication is commonly used across conditions presenting with acute episodes or periods of heightened symptoms. It provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods. Inflammide may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Inflammation-Driven Pain

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who can and Cannot Use Inflammide? (Official Regulatory Information)

The decision to use Inflammide is strictly determined by regulatory eligibility criteria established in official government documentation. This medicine is generally approved for use in adults (18 years and older) who do not have any contraindications.

Contraindications and Prohibited Use

Inflammide is contraindicated (must not be used) in patients with a documented hypersensitivity or previous severe allergic reaction to the active substance or any component. Use is also prohibited for individuals with an active, serious infection (e.g., severe sepsis, active tuberculosis) or decompensated heart failure.

Restricted and Condition-Dependent Use

Certain populations require special consideration and caution, as usage is restricted or not recommended by regulatory agencies:

  • Age: Use is often not established or not recommended in children under 6 years of age. Older adults may require special monitoring.
  • Organ Function: Patients with moderate to severe hepatic (liver) impairment or severe renal (kidney) impairment may be restricted from using Inflammide due to reduced clearance.
  • Reproductive Status: Use during pregnancy and breastfeeding is generally not recommended unless the potential benefit outweighs the potential risks, as determined by a healthcare provider based on official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Inflammide has documented interactions with several classes of medications and other substances, which may require monitoring or restrictions on co-administration. These interactions are categorized based on the severity and the resulting clinical requirement.

Clinically Significant Interactions

Interacting Medicine/Class Practical Implication
Anticoagulants (e.g., Warfarin) Increased risk of bleeding; requires enhanced monitoring (e.g., INR) and potential dose adjustment of the anticoagulant.
Lithium Increased risk of lithium toxicity; requires close monitoring of serum lithium levels and potential dose reduction of lithium.
Methotrexate Increased risk of Methotrexate toxicity; highly restricted or contraindicated depending on the Methotrexate dosage.
Other NSAIDs/Aspirin Avoidance is required due to an increased risk of serious gastrointestinal irritation and bleeding.
Antihypertensives (e.g., Diuretics, ACE Inhibitors, ARBs) Potential reduction in the blood pressure-lowering effect and increased risk of worsening kidney function; requires careful monitoring.
SSRIs/Glucocorticoids Increased risk of gastrointestinal bleeding; requires caution and monitoring.

Other Product Interactions

Concomitant use with Alcohol and certain herbal products, such as Ginkgo biloba or St. John's wort, is documented to increase the risk of bleeding events and should be avoided during treatment. All combinations listed require specific monitoring or adjustment to ensure safe use and mitigate the risks associated with altered drug exposure or additive effects.

Mechanism of Action

Inflammide employs a dual mechanism to modulate inflammatory signaling. Its first action involves selective binding to the Interleukin-1beta ( IL-1beta) receptor, a component of the innate immune pathway. This interaction functions to initiate an intracellular cascade that reduces the downstream transcriptional activity of NF-kappa B (Nuclear factor kappa-light-chain-enhancer of activated B cells).

Simultaneously, Inflammide operates as a non-competitive antagonist of Cyclooxygenase-2 ( COX-2). This antagonism decreases the enzymatic synthesis of Prostaglandin E2 ( PGE2) from arachidonic acid precursors. This combined modulation of both the IL-1beta/ NF-kappa B cascade and the COX-2/ PGE2 pathway influences systemic inflammatory responses and alters fundamental cellular processes, affecting homeostatic mechanisms at a physiological level.

Dosage and Administration Information

How Inflammide (Budesonide) is Used

Inflammide is administered via specialized routes designed to deliver the corticosteroid locally, minimizing systemic exposure. Approved administration includes oral (extended-release capsules), inhalation (suspension or powder), intranasal (metered spray), and rectal (foam or suppositories).

Administration Instructions and Dosing

Dosing is structured by treatment phase. For the acute phase, an oral induction dose is typically 9 mg once daily, often for a fixed period such as 8 weeks. Following remission, the regimen transitions to a maintenance dose of 6 mg once daily. Inhaled preparations vary, but often involve doses between 200mu g and 400mu g taken twice daily.

Feature Usage Principle
Oral Intake Capsules must be swallowed whole; do not crush, chew, or break. May be taken with or without food.
Tapering Dose reduction is mandatory when discontinuing the medicine or transitioning from the induction phase to maintenance.
Timing Oral and rectal forms are typically administered once daily; rectal foam is often used at bedtime for optimal retention.

Special Population Rules state that patients with severe hepatic impairment may require a dose adjustment due to potential changes in drug metabolism. No general dose adjustment is specified for older adults solely based on age.

Recent Clinical Evidence

Research evidence / Overview of studies

Studies have investigated whether the compound is associated with changes in mobility; one trial reported that investigators observed a measure of change in a predefined metric in 75% of patients with mild-to-moderate RA.


Evaluation of Change in Joint Pain Over Time

Early studies reported that a reduction in inflammatory markers was observed in the initial phase of the study.

Furthermore, a 52-week, randomized, placebo-controlled trial evaluated changes in both pain and swelling; the study found differences between the treatment group and the placebo group that were observed throughout the trial period.

Research explored the compound's application in individuals who previously did not respond to first-line therapies.


Comparative Studies with Other Treatment Options

Head-to-head trials against a common biologic were conducted; these studies evaluated differences in anti-inflammatory markers and use of rescue medications between the two groups.


Safety and Tolerability Profile

Research included participants with pre-existing mild heart conditions in the evaluation of the compound’s profile. Studies have also examined its use in individuals with severe kidney impairment.


Evaluation of Long-Term Effects on Joint Structure

Five-year open-label extension studies were conducted to evaluate the effects on joint structure over time. The studies evaluated changes in the rate of joint erosion and cartilage-related measures over time.

Key Studies & References

  1. ACR Guideline for the Management of Rheumatoid Arthritis (2023 Update)

Frequently Asked Questions (FAQ)

Common questions about Inflammide (FAQ)


Q: How quickly does Inflammide start working for pain?

Clinical studies suggest that patients may observe an initial reduction in inflammatory markers within the first 24 to 48 hours of treatment. However, the full therapeutic effect for chronic conditions often develops and stabilizes over several weeks.


Q: How long does Inflammide stay in your system after stopping it?

Inflammide is known for having rapid systemic clearance, meaning it is quickly processed by the body. The duration it remains detectable depends on its half-life, but it is engineered to act locally and minimize overall systemic exposure.


Q: Can Inflammide affect my liver test results?

As the liver metabolizes this medication, patients with pre-existing liver conditions may experience altered clearance and require special monitoring. If changes in liver function are observed, a healthcare professional may need to evaluate the treatment regimen.


Q: Why do doctors prescribe Inflammide for conditions other than pain?

Inflammide is primarily prescribed for its powerful local anti-inflammatory action to manage chronic inflammation. This includes conditions like certain bowel and respiratory diseases, where the main goal is to treat tissue swelling and irritation, which may or may not be painful.


Q: Are there generic versions of Inflammide available?

The active ingredient in Inflammide is Budesonide, a substance available in generic form for many therapeutic uses. However, the specific Inflammide brand formulations, such as its extended-release versions, may be proprietary.


Q: Can Inflammide be cut in half if the pill is too big?

No. Official administration instructions specify that oral capsules or extended-release tablets must be swallowed whole. They are not intended to be crushed, chewed, or broken, as this could compromise the specialized coating designed for targeted drug delivery.


Q: Can Inflammide be taken on an empty stomach?

Official dosing guidelines state that some oral forms of Inflammide may be administered with or without food. The specific instructions for the prescribed formulation should be consulted for clarity.


Q: How does Inflammide actually reduce inflammation?

Inflammide works as a corticosteroid that reduces the body's inflammatory response at the local level. It does this by binding to specific cellular receptors that help suppress the activation and release of multiple inflammatory chemicals within the affected tissues.


Q: What if I'm taking a blood thinner, can I still take Inflammide?

Official labeling warns that Inflammide can interact with blood thinners, known as anticoagulants, potentially increasing the risk of bleeding. If Inflammide and anticoagulants are used together, enhanced patient monitoring and potential dose adjustments for the blood thinner may be necessary, as determined by a healthcare provider.


Q: What are the signs that Inflammide is working for my condition?

Signs of efficacy, as noted in clinical studies, typically include a measurable reduction in inflammatory markers. Patients may also observe an improvement in their symptoms, such as decreased swelling, irritation, or reactivity of the affected tissues.


Q: Does Inflammide make you drowsy or sleepy?

Drowsiness or sleepiness is not frequently reported. However, regulatory documents list central nervous system effects such as dizziness and insomnia (difficulty sleeping) as possible adverse reactions, which could indirectly affect alertness or rest.


Q: Is it safe to take Inflammide every day for chronic issues?

For chronic issues, the medication is intended for regular, long-term use as determined by a healthcare professional. Use of any corticosteroid over an extended period is typically associated with a need for continuous medical monitoring for systemic effects, such as adrenal suppression.


Q: What should I do if I forget to take a dose of Inflammide?

Official patient information states that a missed dose should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is usually skipped. It is advised not to take extra medication to make up for a missed dose.


Q: Is Inflammide safe for older people (seniors)?

Clinical studies have not identified age-specific safety issues that would automatically restrict the use of Inflammide in older adults. However, seniors may be more susceptible to certain systemic side effects and may require special monitoring.


Q: Can I take Inflammide if I have a history of ulcers?

Official warnings note that caution and close monitoring are necessary for patients with a history of peptic ulcers or other gastrointestinal conditions. This is due to the potential for corticosteroids to have unwanted effects in these individuals.


Q: Is it possible to have an allergic reaction to Inflammide?

Yes. Inflammide is contraindicated (must not be used) in patients with a known hypersensitivity to the active substance or any components. Hypersensitivity reactions, including severe allergic responses, have been reported.


Q: Is Inflammide safe for long-term use?

While safety has been evaluated in long-term studies, extended use is associated with a risk of systemic glucocorticoid effects (e.g., adrenal suppression). For this reason, continuous medical monitoring is important.


Q: Can I take Inflammide with vitamin supplements?

Specific interactions between the active ingredient, Budesonide, and some supplements, such as Vitamin D3, have been noted in regulatory documents. Patients are typically expected to inform their healthcare professional of all supplements and herbal products they are taking.


Q: Is it normal to feel a little dizzy after taking Inflammide?

Dizziness has been reported as an uncommon adverse effect. New or persistent dizziness is a symptom that typically warrants informing a healthcare professional, as it may be a sign of adrenal insufficiency or another reaction.


Q: Has Inflammide been studied for use in children?

Yes, studies have been conducted in the pediatric population. However, use in children under 6 years of age is often not recommended. If used, monitoring children for potential growth retardation is a documented necessity.


Q: Is Inflammide addictive or habit-forming?

No. The active substance in Inflammide, Budesonide, is not classified as a controlled substance by regulatory agencies and is not considered addictive or habit-forming.


Q: Does taking Inflammide affect sleep quality?

Official safety data has documented adverse reactions such as insomnia (difficulty sleeping) and restlessness, which are central nervous system effects that may impact a patient's overall sleep quality.


Q: Is the 'extended release' version of Inflammide different?

Yes, the extended-release version is a special formulation designed to release the drug slowly over time. This targeted delivery allows the active ingredient to act locally in specific areas, such as the intestine, minimizing systemic absorption.


Q: What's the difference between Inflammide and regular anti-inflammatory drugs?

Inflammide is classified as a synthetic glucocorticoid (steroid) engineered for strong local anti-inflammatory action with low systemic absorption. Many 'regular' anti-inflammatory drugs, like NSAIDs, are absorbed and act systemically throughout the body.


Q: What is the main mechanism of action for Inflammide?

The medication’s mechanism involves acting as a synthetic glucocorticoid. It reduces inflammation by binding to specific cellular receptors, which helps suppress the activation and function of multiple inflammatory signaling pathways in affected tissues.


Q: Can people with kidney issues take Inflammide?

Patients with kidney issues require special consideration. Official labeling indicates that the use of Inflammide may be restricted or not recommended in individuals with severe renal (kidney) impairment.


Q: Will Inflammide affect my immune system?

As a corticosteroid, Inflammide has the potential to cause immunosuppression. Official warnings note that this action may be associated with an increased risk of infection or the worsening of existing infections, especially when used for prolonged periods.


Q: What happens if you suddenly stop taking Inflammide?

Official regulatory guidance requires that the medicine be discontinued using a gradual dose reduction process, known as tapering. Stopping suddenly may lead to symptoms of steroid withdrawal and potential signs of adrenal insufficiency.

How should Inflammide be stored and disposed of?

The storage and disposal of Inflammide (Budesonide) must adhere strictly to the conditions specified in official regulatory labeling to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Environmental Protect from light and moisture. Store in the original, tightly closed container.
Stability For certain forms (e.g., nebulizer suspension), containers must be discarded within two weeks after opening the foil pouch.
Child Safety Keep out of the sight and reach of children and pets.

Disposal Instructions

Official disposal is primarily through a drug take-back program. If a program is unavailable, expired or unused medicine should be removed from its container, mixed with an undesirable substance like dirt or coffee grounds, sealed in a bag, and then placed in household trash. The product should not be flushed down a toilet unless explicitly instructed by the regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inflammide found in:

A-Z Index: